Tecovirimat
CAS No. : 869572-92-9
(Synonyms: ST-246)
| Size | Price | Stock |
|---|---|---|
| 5mg | $260 | In-stock |
| 10mg | $400 | In-stock |
| 25mg | $780 | In-stock |
| 50mg | $1345 | In-stock |
| 100mg | $1880 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-14805 |
| M.Wt: | 376.33 |
| Formula: | C19H15F3N2O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Tecovirimat (ST-246) is an orally bioavailable and selective compound against orthopoxviruses including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus[1][2][3][4][5].
In Vitro:Tecovirimat (0-50 μM, 3 days) is a potent and specific inhibitor of orthopoxvirus replication that is active against a broad spectrum of orthopoxviruses[1].
In Vivo:Tecovirimat (50 mg/kg, oral gavage, twice a day for 14 days) mounts a protective immune response to vaccinia virus infection in a lethal intranasal vaccinia virus challenge model of mice[1].
Tecovirimat (50 mg/kg, oral gavage, 5 days) can inhibit vaccinia virus-induced lesion formation following i.v. viral inoculation in Vaccinia virus-mouse tail lesion model[1].
Tecovirimat (100 mg/kg, p.o., daily for various durations of 5, 7, 10, or 14 days) significantly decreases in mortality of cowpox virus (CV)-infected mice[2].
Pharmacokinetic parameters of Tecovirimat administered by oral gavage in mice[1]
| Dosage (mg/kg) | Tmax (h) | Cmax (μg/mL) | AUC0-t (μg·h/mL) | T1/2 (h) |
| 30 | 2.7 | 32.5 | 284.2 | 2.5 |
| 100 | 1.0 | 62.2 | 287.6 | 2.5 |